A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study

BACKGROUND: Platinum-based combinations are the standard second-line treatment for platinum-sensitive ovarian cancer (OC). This randomized phase II study was undertaken in order to compare the combination of carboplatin and pegylated liposomal doxorubicin (LD) with carboplatin and paclitaxel (CP) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Bafaloukos, Dimitrios, Linardou, Helena, Aravantinos, Gerasimos, Papadimitriou, Christos, Bamias, Aristotelis, Fountzilas, George, Kalofonos, Haralabos P, Kosmidis, Paris, Timotheadou, Eleni, Makatsoris, Thomas, Samantas, Epaminondas, Briasoulis, Evangelos, Christodoulou, Christos, Papakostas, Pavlos, Pectasides, Dimitrios, Dimopoulos, Athanasios M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823653/
https://www.ncbi.nlm.nih.gov/pubmed/20055981
http://dx.doi.org/10.1186/1741-7015-8-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823653/
https://www.ncbi.nlm.nih.gov/pubmed/20055981
http://dx.doi.org/10.1186/1741-7015-8-3

Ejemplares similares